0001213900-21-049786.txt : 20210924 0001213900-21-049786.hdr.sgml : 20210924 20210924160737 ACCESSION NUMBER: 0001213900-21-049786 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20210924 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210924 DATE AS OF CHANGE: 20210924 FILER: COMPANY DATA: COMPANY CONFORMED NAME: InMed Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001728328 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39685 FILM NUMBER: 211277332 BUSINESS ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 BUSINESS PHONE: (604) 669-7207 MAIL ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 8-K 1 ea147907-8k_inmedpharm.htm CURRENT REPORT
0001728328 false A1 0001728328 2021-09-24 2021-09-24 0001728328 dei:FormerAddressMember 2021-09-24 2021-09-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 24, 2021

 

 

 

INMED PHARMACEUTICALS INC.

(Exact Name of Company as Specified in Charter)

 

 

 

British Columbia   001-39685   98-1428279

(State or Other Jurisdiction

of Incorporation)

  

(Commission File Number)

  

(IRS Employer

Identification No.)

 

InMed Pharmaceuticals Inc.

Suite 310 - 815 W. Hastings Street,

Vancouver, B.C.

Canada

   V6C 1B4
(Address of Principal Executive Offices)   (Zip Code)

 

Company’s telephone number, including area code: (604) 669-7207

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading

Symbol(s)

   Name of each exchange
on which registered
Common Shares, no par value   INM   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company  ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On September 24, 2021, the Company reported financial results for the fiscal year ended June 30, 2021.

 

The information set forth in this Item 7.01, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01.Financial Statements and Exhibits.

 

(d) Exhibits:

 

The following exhibits shall be deemed to be furnished, and not filed:

 

Exhibit No.   Description
99.1   News release, dated September 24, 2021
104   Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INMED PHARMACEUTICALS INC.
   
Date: September 24, 2021 By:

/s/ Bruce Colwill

   

Bruce Colwill

Chief Financial Officer

 

 

2

 

 

 EX-99.1 2 ea147907ex99-1_inmedpharma.htm NEWS RELEASE, DATED SEPTEMBER 24, 2021

Exhibit 99.1

 

 

 

NASDAQ: INM

 

Suite 310-815 W. Hastings St.

Vancouver, BC, Canada V6C 1B4

Tel: +1.604.669.7207

Email: info@inmedpharma.com

www.inmedpharma.com

 

InMed Pharmaceuticals Reports Full Year Fiscal 2021 Financial Results and Provides Business Update

 

Vancouver, BC – September 24, 2021 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, today reported financial results for the fiscal year ended June 30, 2021.

 

Conference Call & Webcast:

Friday, September 24, 2021, at 8:00 AM Pacific Time, 11:00 AM Eastern Time

US/CANADA Participant Toll-Free Dial-In Number: +1 (855) 605-1745

US/CANADA Participant International Dial-In Number: +1 (914) 987-7959

Conference ID: 9373618

Webcast: https://edge.media-server.com/mmc/p/ny89uo2r

(*Webcast replay available for 90 days)

 

The Company’s full financial statements and related MD&A for the fiscal year ended June 30, 2021, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov.

 

Eric A. Adams, InMed CEO, states, “In the final quarter of our of fiscal year 2021, as well as throughout the year, we made important progress in corporate development, pharmaceutical drug development and in advancing our proprietary manufacturing approach, IntegraSyn™. With the recent announcements regarding our acquisition of BayMedica Inc., the Company is well positioned to continue its activities to solidify a leadership position in the field of rare cannabinoids.”

 

Business Update:

 

●Corporate Development. On June 29, 2021, the Company announced it had entered into a non-binding letter of intent (the “LOI”) to acquire BayMedica Inc. (“BayMedica”), a private company based in the U.S. that specializes in the manufacture and commercialization of rare cannabinoids and on September 13, 2021, the Company announced the signing of a Definitive Agreement (“Definitive Agreement”) related to the acquisition. The transaction, which is subject to certain standard closing conditions, is expected to close in the coming weeks. Upon closing, InMed will become a global leader in the manufacturing of rare cannabinoids, with expertise in three distinct and complementary cannabinoid manufacturing approaches. InMed’s proprietary cannabinoid manufacturing process, IntegraSyn™, combined with BayMedica’s synthetic biology and chemical synthesis capabilities, will provide InMed with the requisite flexibility to select the most appropriate, cost-effective manufacturing method based on the target cannabinoid and appropriate quality specifications for the desired market segment. In addition to cannabinoid manufacturing, the combined company will continue to explore the therapeutic potential of cannabinoids and novel cannabinoid analogs for pharmaceutical drug development, as well as expand commercial sales of rare cannabinoids to the consumer health and wellness sector.

 

 

 

●IntegraSynTM. On April 26, 2021, the Company announced that its IntegraSyn™ cannabinoid manufacturing approach had achieved a level of 2g/L cannabinoid yield, a milestone that signaled commercial viability and supported the advancement to large-scale commercial production. Subsequent to this, on June 17, 2021, InMed announced that its continued optimization of IntegraSyn™ had resulted in increasing the cannabinoid yield to a level of 5 g/L, significantly exceeding currently reported industry yields and further improving the economics of this proprietary manufacturing approach. The impact of improved yield is a significant reduction in the overall cost of manufacturing due to increased cannabinoid production per batch. InMed is now focused on manufacturing scale-up to larger batch sizes.

 

●INM-755 for the treatment of epidermolysis bullosa (“EB”). On April 28, 2021, InMed announced it had filed Clinical Trial Applications (“CTAs”) in multiple countries for its multi-site Phase 2 clinical trial of INM-755 (cannabinol) cream in Epidermolysis Bullosa (“EB”). To date, CTA’s have now been filed in all 7 participating countries: Austria, France, Germany, Greece, Italy, Israel and Serbia. This INM-755-201 study is designed to enroll up to 20 patients, conservatively within 12 months. All four subtypes of inherited EB, being EB Simplex, Dystrophic EB, Junctional EB, and Kindler Syndrome, are eligible for this study in which InMed will evaluate the safety of INM-755 (cannabinol) cream and its preliminary efficacy in treating symptoms and wound healing over a 28-day period. The study will use a within-patient, double-blind design whereby matched index areas will be randomized to be treated with either INM-755 (cannabinol) cream or vehicle cream as a control. The Company anticipates the patient enrollment to start in the coming weeks.

 

●INM-088 for the treatment of glaucoma. On August 17, 2021, InMed presented preclinical data at the H.C. Wainwright Ophthalmology Conference demonstrating that cannabinol was effective at providing neuroprotection to the retina ganglion cells and reducing intraocular pressure in glaucoma models. Over the past quarter, InMed has continued to set up a larger scale drug product manufacturing process, completed dose-ranging studies and conducted topline clinical design work with its clinical research organization. The drug product produced from the larger scale will be used to support the upcoming GLP studies while the dose-ranging studies will assist in providing guidance on the appropriate dosing level and regimen needed for the GLP studies. Currently, we anticipate the GLP studies to be completed by mid-2022.

 

Financing Activities and Results of Operations (expressed in US Dollars):

 

●On April 27, 2021, InMed announced that, based on the strong trading data on the Nasdaq, it had provided written notice to the Toronto Stock Exchange (the “TSX”) regarding the voluntary delisting of its common shares. InMed’s common shares were delisted from the TSX at the close of trading on May 7, 2021. InMed’s common shares continue to be listed and tradable on the Nasdaq under the symbol “INM”.

 

●On June 29, 2021, the Company announced that it had entered into securities purchase agreement with an institutional investor to raise approximately US$12.0 million and on July 2, 2021, the Company announced that it had closed the private placement. Under the terms of the private placement, an aggregate of 4,036,327 common shares (or common share equivalents in lieu thereof) and warrants to purchase up to an aggregate of 4,036,327 common shares, at an effective purchase price of US$2.973 per common share (or common stock equivalent in lieu thereof) and associated warrant. The warrants have an exercise price of US$2.848 per share, are exercisable immediately and have a term of five years. After deducting the placement agent fees and estimated offering expenses payable by the Company, the Company received net proceeds of approximately US$11.0 million.

 

2

 

 

●For the year ended June 30, 2021, the Company recorded a net loss of $10.2 million, or $1.52 per share, compared with a net loss of $8.9 million, or $1.71 share, for the year ended June 30, 2020.

 

●Research and development and patents expenses were $5.3 million for the year ended June 30, 2021, compared with $5.8 million for the year ended June 30, 2020. The reduction in research and development and patents expenses was primarily due to decreased purchases of the active pharmaceutical ingredients used in INM-755 clinical trials. In addition, share-based payments were $0.3 million lower for the year ended June 30, 2021 while contract research organization (“CRO”) expenditures increased by $0.2 million relative to the prior year.

 

●The Company incurred general and administrative expenses of $4.5 million for the year ended June 30, 2021, compared with $3.2 million for the year ended June 30, 2020. The increase results from a combination of changes including substantially higher insurance fees and higher personnel expenses, partially offset by lower share-based payments and lower investor relation expenses.

 

●The Company also incurred non-cash, share-based payments in connection with the grant of stock options, of $0.6 million for the year ended June 30, 2021 compared with $1.0 million for the year ended June 30, 2020. Share-based payments amounts are included within research and development expenses and general and administrative expenses.

 

●At June 30, 2021, the Company’s cash, cash equivalents and short-term investments were $7.4 million, which compares to $5.8 million at June 30, 2020. The increase in cash, cash equivalents and short-term investments during the year ended June 30, 2021, was primarily the result of the November 16, 2020 public offering and the February 16, 2021 private placement partially offset by cash outflows from operating activities.

 

●At June 30, 2021, the Company’s total issued and outstanding shares were 8,050,707. During the year ended June 30, 2021, the weighted average number of common shares was 6,719,830, which is used for the calculation of loss per share for the year.

 

3

 

 

Table 1: Consolidated statements of financial position:

 

InMed Pharmaceuticals Inc.

CONSOLIDATED BALANCE SHEETS

As at June 30, 2021 and 2020

Expressed in U.S. Dollars

 

  

June 30,

2021

   June 30,
2020		 
ASSETS  $   $ 
Current          
Cash and cash equivalents   7,363,126    5,805,809 
Short-term investments   46,462    42,384 
Accounts receivable   11,919    45,344 
Prepaids and other assets   956,762    418,920 
Total current assets   8,378,269    6,312,457 
Non-Current          
Property and equipment, net   326,595    403,485 
Intangible assets, net   1,061,697    1,086,655 
Other assets   14,655    - 
Total Assets   9,781,216    7,802,597 
LIABILITIES AND SHAREHOLDERS' EQUITY          
Current          
Accounts payables and accrued liabilities   2,134,878    1,607,303 
Current portion of lease obligations   80,483    68,965 
Total current liabilities   2,215,361    1,676,268 
Non-current          
Lease obligations   189,288    248,011 
Total Liabilities   2,404,649    1,924,279 
Shareholders' Equity          
Common shares, no par value, unlimited authorized shares:          
8,050,707 (June 30, 2020 - 5,220,707) issued and outstanding   60,587,417    53,065,240 
Additional paid-in capital   21,513,051    17,764,333 
Accumulated deficit   (74,852,470)   (64,649,381)
Accumulated other comprehensive income (loss)   128,569    (301,874)
Total Shareholders' Equity   7,376,567    5,878,318 
Total Liabilities and Shareholders' Equity   9,781,216    7,802,597 

 

4

 

 

Table 2: Consolidated statements of operations and comprehensive loss:

 

InMed Pharmaceuticals Inc.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

For the year ended June 30, 2021 and 2020

Expressed in U.S. Dollar

 

   Year Ended
June 30		 
   2021   2020 
   $   $ 
Operating Expenses        
Research and development and patents   5,338,084    5,811,266 
General and administrative   4,479,333    3,227,167 
Amortization and depreciation   120,866    112,429 
Total operating expenses   9,938,283    9,150,862 
           
Other Income (Loss)          
Interest income   16,017    129,526 
Finance expense   (360,350)   - 
Unrealized gain on derivative warrants liability   242,628    - 
Foreign exchange (loss) gain   (163,101)   82,187 
Net loss for the period   (10,203,089)   (8,939,149)
           
Other Comprehensive Loss          
Foreign currency translation gain (loss)   430,443    (419,838)
Total comprehensive loss for the period   (9,772,646)   (9,358,987)
           
Net loss per share for the year          
Basic and diluted   (1.52)   (1.71)
Weighted average outstanding common shares          
Basic and diluted   6,719,830    5,220,707 

 

5

 

 

Table 3: Consolidated statements of cash flows:

 

InMed Pharmaceuticals Inc.

CONSOLIDATED STATEMENTS OF CASH FLOWS

For the years ended June 30, 2021 and 2020

Expressed in U.S. Dollars

 

   2021   2020 
   $   $ 
Cash provided by (used in):        
Operating Activities        
Net loss for the period   (10,203,089)   (8,939,149)
Items not requiring cash:          
Amortization and depreciation   120,866    112,429 
Share-based compensation   610,193    994,401 
Non-cash lease expense   107,828    89,816 
Loss on disposal of assets   555    2,307 
Received interest income on short-term investments   131    79,937 
Unrealized gain on derivative warrants liability   (242,628)   - 
Unrealized foreign exchange gain   (445)   - 
Payments on lease obligations   (93,951)   (72,522)
Finance expense   360,350    - 
Changes in non-cash working capital:        - 
Prepaids and other assets   (823,172)   (126,560)
Other non-current assets   (14,161)   - 
Accounts receivable   40,198    17,273 
Accounts payable and accrued liabilities   346,685    467,392 
Total cash used in operating activities   (9,790,640)   (7,374,676)
Investing Activities          
Maturity of short-term investments   -    3,876,269 
Purchase of short-term investments   -    (43,619)
Proceeds on disposal of property and equipment   -    541 
Purchase of property and equipment   (1,725)   (42,573)
Total cash (used in) provided by investing activities   (1,725)   3,790,618 
Financing Activities          
Shares issued for cash   12,472,500    - 
Share issuance costs   (1,617,778)   (30,993)
Total cash provided by (used in) financing activities   10,854,722    (30,993)
Effects of foreign exchange on cash and cash equivalents   494,960    (416,353)
Increase (decrease) in cash during the period   1,557,317    (4,031,404)
Cash and cash equivalents beginning of the period   5,805,809    9,837,213 
Cash and cash equivalents end of the period   7,363,126    5,805,809 

 

6

 

 

About InMed: InMed Pharmaceuticals is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol (“CBN”) and is developing IntegraSyn™ to produce pharmaceutical-grade cannabinoids. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com.

 

Investor Contact:

Colin Clancy

Senior Director, Investor Relations

T: +1 604 416 0999

E: cclancy@inmedpharma.com

 

Edison Group:

Joe Green/Laine Yonker

T: +1.646.653.7030/+1.646.653.7035

E: jgreen@edisongroup.com / lyonker@edisongroup.com

 

Cautionary Note Regarding Forward-Looking Information:

 

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: leading the way in the clinical development of cannabinol (“CBN”); developing a pipeline of cannabinoid-based medications in diseases with high unmet medical need; delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines; leading the clinical development of cannabinol as a potential therapeutic option for diseases; solidifying a leadership position in the field of rare cannabinoids including in the manufacturing of rare cannabinoids; scaling-up IntegraSyn™ to larger batch sizes; evaluating the safety of INM-755 (cannabinol) cream and its preliminary efficacy in the INM-755-201 study; commencing patient enrollment the INM-755-201 study in the coming weeks; and completing INM-088 GLP studies by mid-2022.

 

With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: continued and timely positive preclinical and clinical efficacy data; the speed of regulatory approvals; the ability to contract with suitable partners; demand for InMed’s products; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.

 

Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: the outbreak and impact of COVID-19 may worsen; preclinical and clinical testing may not produce the desired results on a timely basis, or at all; regulatory applications may not be approved on a timely basis, or at all; cannabis licensing/importing issues may delay our projected development timelines; suitable partners may not be located; economic or market conditions may worsen; our existing cash runway may not allow us to complete our forthcoming significant milestones; the development of a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs may not be as successful as desired, if at all. A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed’s Form 10-K filed on sec.gov.

 

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

 

 

7

 

 

 EX-101.SCH 3 inm-20210924.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 inm-20210924_def.xml XBRL DEFINITION FILE EX-101.LAB 5 inm-20210924_lab.xml XBRL LABEL FILE Entity Addresses, Address Type [Axis] Former Address [Member] Entity Addresses [Table] Entity Addresses [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 inm-20210924_pre.xml XBRL PRESENTATION FILE GRAPHIC 7 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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end XML 8 ea147907-8k_inmedpharm_htm.xml IDEA: XBRL DOCUMENT 0001728328 2021-09-24 2021-09-24 0001728328 dei:FormerAddressMember 2021-09-24 2021-09-24 iso4217:USD shares iso4217:USD shares 0001728328 false A1 8-K 2021-09-24 INMED PHARMACEUTICALS INC. 001-39685 98-1428279 Suite 310 - 815 W. Hastings Street, Vancouver, B.C. CA V6C 1B4 (604) 669-7207 669-7207 false false false false Common Shares, no par value INM NASDAQ true false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Sep. 24, 2021
Entity Addresses [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 24, 2021
Entity File Number 001-39685
Entity Registrant Name INMED PHARMACEUTICALS INC.
Entity Central Index Key 0001728328
Entity Tax Identification Number 98-1428279
Entity Incorporation, State or Country Code A1
Entity Address, Address Line One Suite 310 - 815 W. Hastings Street,
Entity Address, City or Town Vancouver, B.C.
Entity Address, Country CA
Entity Address, Postal Zip Code V6C 1B4
City Area Code (604)
Local Phone Number 669-7207
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, no par value
Trading Symbol INM
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Former Address [Member]  
Entity Addresses [Line Items]  
Entity Address, Postal Zip Code 669-7207
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 2 96 1 false 1 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://inmedpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea147907-8k_inmedpharm.htm ea147907ex99-1_inmedpharma.htm inm-20210924.xsd inm-20210924_def.xml inm-20210924_lab.xml inm-20210924_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea147907-8k_inmedpharm.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 2, "dts": { "definitionLink": { "local": [ "inm-20210924_def.xml" ] }, "inline": { "local": [ "ea147907-8k_inmedpharm.htm" ] }, "labelLink": { "local": [ "inm-20210924_lab.xml" ] }, "presentationLink": { "local": [ "inm-20210924_pre.xml" ] }, "schema": { "local": [ "inm-20210924.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 64, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 1, "nsprefix": "INM", "nsuri": "http://inmedpharma.com/20210924", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea147907-8k_inmedpharm.htm", "contextRef": "From2021-09-24to2021-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://inmedpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea147907-8k_inmedpharm.htm", "contextRef": "From2021-09-24to2021-09-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 1, "tag": { "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r12", "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityAddressesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Addresses [Line Items]" } } }, "localname": "EntityAddressesLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityAddressesTable": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Container of address information for the entity", "label": "Entity Addresses [Table]" } } }, "localname": "EntityAddressesTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_FormerAddressMember": { "auth_ref": [ "r11", "r14" ], "lang": { "en-us": { "role": { "documentation": "Former address for entity", "label": "Former Address [Member]" } } }, "localname": "FormerAddressMember", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 10-Q", "Number": "249", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r12": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r13": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r14": { "Name": "Form 8-K", "Number": "249", "Publisher": "SEC", "Section": "308" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r17": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r20": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 17 0001213900-21-049786-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-21-049786-xbrl.zip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